Chiasma's private decision

Why Chiasma and VCs opted for a $70M series E rather than an IPO

Chiasma Inc. profiles as a potential IPO candidate with a late-stage asset on the verge of registration. But MPM Capital's Todd Foley told BioCentury that the recent unexpected return of commercial rights for its octreotide acetate to treat acromegaly meant the timing wasn't right.

Instead, Chiasma's investors

Read the full 473 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE